Clinical trial
A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis…
NCT03551522 · Gilead Sciences, Industry · Terminated
Key facts
| NCT number | NCT03551522 |
|---|---|
| Title | A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH) |
| Official title | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH) |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | NASH - Nonalcoholic Steatohepatitis |
| Intervention type | Drug |
| Interventions | Seladelpar, Placebos |
| Enrollment | 181 |
| Start date | Apr 30, 2018 |
| Primary completion | May 8, 2019 |
| Completion | Aug 10, 2020 |
| First posted | Jun 11, 2018 |
| Last update posted | Sep 15, 2022 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: